Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two distinct indications: treatment of type 2 diabetes mellitus (Mounjaro) and chronic weight management (Zepbound)
Fasting State: Administration on an empty stomach (e.g., 30-60 minutes before a meal or several hours after) is often recommended for GH-releasing peptides
8-year trends in obesity, type 2 diabetes, and glucagon-like peptide-1 (GLP-1) use in patients with obstructive sleep apnea
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists, such as semaglutide (Wegovy) or tirzepatide (Zepbound), reduce hunger and cravings, making it easier to maintain a calorie deficit during plateaus
US$ 28.85
US$ 21.15
US$ 23.26
US$ 21.03
US$ 20.52
US$ 24.80
US$ 27.35
US$ 22.05
